Next Article in Journal
Na+, K+-ATPase Signaling and Bipolar Disorder
Previous Article in Journal
Liquid Biopsy in Endometrial Cancer: New Opportunities for Personalized Oncology
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2018, 19(8), 2312; https://doi.org/10.3390/ijms19082312

CTLA-4 Mediates Inhibitory Function of Mesenchymal Stem/Stromal Cells

1
Department of Rheumatology and Clinical Immunology, Charité–Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, 10117 Berlin, Germany
2
German Rheumatism Research Centre (DRFZ) Berlin, A Leibniz Institute, 10117 Berlin, Germany
3
Department of Orthopedics, Campus Eisenberg, Jena University Hospital, Klosterlausnitzer Straße 81, 07607 Eisenberg, Germany
4
Endokrinologikum Berlin, 10117 Berlin, Germany
*
Authors to whom correspondence should be addressed.
Received: 28 June 2018 / Revised: 1 August 2018 / Accepted: 2 August 2018 / Published: 7 August 2018
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)
View Full-Text   |   Download PDF [1363 KB, uploaded 7 August 2018]   |  

Abstract

Mesenchymal stem/stromal cells (MSCs) are stem cells of the connective tissue, possess a plastic phenotype, and are able to differentiate into various tissues. Besides their role in tissue regeneration, MSCs perform additional functions as a modulator or inhibitor of immune responses. Due to their pleiotropic function, MSCs have also gained therapeutic importance for the treatment of autoimmune diseases and for improving fracture healing and cartilage regeneration. However, the therapeutic/immunomodulatory mode of action of MSCs is largely unknown. Here, we describe that MSCs express the inhibitory receptor CTLA-4 (cytotoxic T lymphocyte antigen 4). We show that depending on the environmental conditions, MSCs express different isoforms of CTLA-4 with the secreted isoform (sCTLA-4) being the most abundant under hypoxic conditions. Furthermore, we demonstrate that the immunosuppressive function of MSCs is mediated mainly by the secretion of CTLA-4. These findings open new ways for treatment when tissue regeneration/fracture healing is difficult. View Full-Text
Keywords: mesenchymal stem/stromal cells; immune modulation; CTLA-4; hypoxia; fracture healing; regeneration mesenchymal stem/stromal cells; immune modulation; CTLA-4; hypoxia; fracture healing; regeneration
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Gaber, T.; Schönbeck, K.; Hoff, H.; Tran, C.L.; Strehl, C.; Lang, A.; Ohrndorf, S.; Pfeiffenberger, M.; Röhner, E.; Matziolis, G.; Burmester, G.-R.; Buttgereit, F.; Hoff, P. CTLA-4 Mediates Inhibitory Function of Mesenchymal Stem/Stromal Cells. Int. J. Mol. Sci. 2018, 19, 2312.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top